Haplotype-resolved de novo assembly of the Vero cell line genome

被引:0
作者
Marie-Angélique Sène
Sascha Kiesslich
Haig Djambazian
Jiannis Ragoussis
Yu Xia
Amine A. Kamen
机构
[1] McGill University,Department of Bioengineering
[2] McGill Genome Center,undefined
来源
npj Vaccines | / 6卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The Vero cell line is the most used continuous cell line for viral vaccine manufacturing with more than 40 years of accumulated experience in the vaccine industry. Additionally, the Vero cell line has shown a high affinity for infection by MERS-CoV, SARS-CoV, and recently SARS-CoV-2, emerging as an important discovery and screening tool to support the global research and development efforts in this COVID-19 pandemic. However, the lack of a reference genome for the Vero cell line has limited our understanding of host–virus interactions underlying such affinity of the Vero cell towards key emerging pathogens, and more importantly our ability to redesign high-yield vaccine production processes using Vero genome editing. In this paper, we present an annotated highly contiguous 2.9 Gb assembly of the Vero cell genome. In addition, several viral genome insertions, including Adeno-associated virus serotypes 3, 4, 7, and 8, have been identified, giving valuable insights into quality control considerations for cell-based vaccine production systems. Variant calling revealed that, in addition to interferon, chemokines, and caspases-related genes lost their functions. Surprisingly, the ACE2 gene, which was previously identified as the host cell entry receptor for SARS-CoV and SARS-CoV-2, also lost function in the Vero genome due to structural variations.
引用
收藏
相关论文
共 78 条
[1]  
Kiesslich S(2020)Vero cell upstream bioprocess development for the production of viral vectors and vaccines Biotech. Adv. 44 107608-618
[2]  
Kamen AA(2009)Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines Exp. Rev. Vacc. 8 607-2113
[3]  
Barrett PN(2018)The vesicular stomatitis virus-based Ebola virus vaccine: from concept to clinical trials Hum. Vaccin. Immunother. 14 2107-1704
[4]  
Mundt W(2016)Engineering enhanced vaccine cell lines to eradicate Vaccine-preventable diseases: the polio end game J. Virol. 90 1694-683
[5]  
Kistner O(2014)The genome landscape of the african green monkey kidney-derived vero cell line DNA Res. 21 673-38
[6]  
Howard MK(2018)A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization Antivir. Res. 150 30-280.e8
[7]  
Suder E(2020)SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Cell. 181 271-1933
[8]  
Furuyama W(2015)The genome of the vervet (Chlorocebus aethiops sabaeus) Genome Res. 25 1921-3212
[9]  
Feldmann H(2015)BUSCO: assessing genome assembly and annotation completeness with single-copy orthologs Bioinforma. 31 3210-1067
[10]  
Marzi A(2007)CEGMA: a pipeline to accurately annotate core genes in eukaryotic genomes Bioinforma. 23 1061-3637